Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results Proactive Investors (Australia) 3d
The Small Cap Wrap: Actinogen Medical targets Alzheimer’s treatment gap; Percheron Phase II progress supports Edison’s 5.5-cent valuation Proactive Investors (Australia) 3d
Actinogen Medical targets Alzheimer’s treatment gap in projected $20BN market Proactive Investors (Australia) 3d
Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI Proactive Investors (US) 8d
Woman with Alzheimer’s ‘regains mobility after magic mushrooms’ The Independent 2d Neuroscience Health Science Article paywall
There are new blood tests for Alzheimer’s. Should I have one? The Conversation (AU) 4d Australia Health Science
‘A completely new person’: can surgery help Alzheimer’s patients regain basic skills? South China Morning Post 5d Hong Kong China
ASIC reaches auditors and a new offshore vehicle in a$1.1 Billion super collapse Finance Magnates 5d ASIC Australia Australian Real Estate All sources
Shares soar to record highs as oil dives on peace hopes The North West Star 3d Australia Iran Business (US) All sources
Mining giant Glencore looks beyond London with secondary ASX listing OilPrice.com 2d Glencore Australia Global Stock Markets All sources
Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results Proactive Investors (Australia) 3d Actinogen Medical Alzheimer's Biotechnology All sources
